When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Premenstrual syndrome and dysphoric disorder

Последний просмотренный: 30 May 2025
Last updated: 08 Feb 2024

Резюме

Определение

Анамнез и осмотр

Ключевые диагностические факторы

  • abdominal bloating
  • fatigue
  • breast tenderness
  • headaches
  • depressed mood, irritability, and internal tension
  • labile mood
  • adverse effect on life
Полная информация

Другие диагностические факторы

  • increased appetite
  • forgetfulness and difficulty concentrating
  • other subjective symptoms
  • insomnia or hypersomnia
  • gastrointestinal upset
  • heart palpitations
  • hot flashes
Полная информация

Факторы риска

  • postpubescent and premenopausal women
  • family history
  • mood disorders
  • cigarette smoking
  • white women
  • sexual abuse and/or trauma
  • alcohol consumption
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • prospective symptom diary
Полная информация

Исследования, проведение которых нужно рассмотреть

  • thyroid function tests
  • follicle-stimulating hormone levels
  • depression screening
  • CBC
Полная информация

Алгоритм лечения

ПРОДОЛЖЕНИЕ

mild PMS

moderate to severe PMS or PMDD

Составители

Авторы

Nancy A. Phillips, MD

Associate Professor

Department of Obstetrics, Gynecology and Reproductive Sciences

Rutgers Robert Wood Johnson Medical School

New Brunswick

NJ

Раскрытие информации

NAP has been reimbursed by Synexis Pharma, manufacturer of Ibrexafungerp, for attending advisory boards. NAP is on the North American Board of the North American chapter of the ISSVD (International Society for the Study of Vulvovaginal Disease). NAP has received grants from Syneos for a study on Myfembree.

Gloria Bachmann, MD

Professor

Department of Obstetrics, Gynecology and Reproductive Sciences

Rutgers Robert Wood Johnson Medical School

New Brunswick

NJ

Раскрытие информации

GB declares that she has no competing interests.

Выражение благодарностей

Dr Nancy A. Phillips and Dr Gloria Bachmann would like to gratefully acknowledge Professor Margaret Rees and Dr Desiree Lie, the previous contributors to this topic.

Раскрытие информации

MR and DL declare that they have no competing interests.

Рецензенты

Julianne Toohey, MD

Obstetrician-Gynecologist

Department of Obstetrics and Gynecology

University of California Irvine Medical Center

Orange

CA

Раскрытие информации

JT declares that she has no competing interests.

Carol Henshaw, MB ChB, MD

Consultant in Perinatal Mental Health

Liverpool Women's NHS Foundation Trust

Liverpool

UK

Раскрытие информации

CH declares that she has no competing interests.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

American College of Obstetricians and Gynecologists. ACOG clinical practice guideline no. 7: management of premenstrual disorders. Dec 2023 [internet publication].Полный текст

Ismaili E, Walsh S, O'Brien PMS, et al; Consensus Group of the International Society for Premenstrual Disorders. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health. 2016 Dec;19(6):953-8. Аннотация

Green LJ, O’Brien PMS, Panay N, et al; Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome: green-top guideline no. 48. BJOG. 2017 Feb;124(3):e73-105.Полный текст  Аннотация

World Health Organization. International classification of diseases 11th revision. Jan 2022 [internet publication].Полный текст

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности